Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-018-2178-0
Abstract: Anti-PD-1 and anti-CTLA-4 antibodies cause immune-related side effects such as autoimmune type 1 diabetes (T1D). It has also been suggested that by increasing TNF-α, IL-2 and IFN-γ production, anti-PD-1 and/or anti-CTLA-4 treatment could affect pancreatic… read more here.
Keywords: anti ctla; anti anti; anti; type diabetes ... See more keywords
Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.
Sign Up to like & getrecommendations! Published in 2022 at "Translational oncology"
DOI: 10.1016/j.tranon.2022.101405
Abstract: The recent development of immunotherapy represents a significant breakthrough in cancer therapy. Several immunotherapies provide robust efficacy gains in a wide variety of cancers. However, in some patients the immune checkpoint blockade remains ineffective due… read more here.
Keywords: tumor; cancer; breast; anti ctla ... See more keywords
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Cancer"
DOI: 10.1038/bjc.2016.429
Abstract: Background:Although there are reports that metronomic cyclophosphamide (CTX) can be immune stimulating, the impact of its combination with anti-CTLA-4 immunotherapy for the treatment of cancer remains to be evaluated.Methods:Murine EMT-6/P breast cancer, or its cisplatin… read more here.
Keywords: anti ctla; ctla; ctx; breast cancer ... See more keywords
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Cell Research"
DOI: 10.1038/s41422-019-0184-1
Abstract: It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet suboptimal cancer immunotherapeutic effects (CITE). Here we report that while irAE-prone Ipilimumab and TremeIgG1… read more here.
Keywords: anti ctla; ctla antibodies; ctla; cancer ... See more keywords
pH-sensitive anti-CTLA4 antibodies: yes to efficacy, no to toxicity
Sign Up to like & getrecommendations! Published in 2019 at "Cell Research"
DOI: 10.1038/s41422-019-0198-8
Abstract: For a long time, anti-CTLA-4 antibodies were believed to mediate their beneficial cancer immunotherapeutic effect (CITE), whose effectiveness and safety are limited by associated immune-related adverse effects (irAE), via blocking the interaction between CTLA-4 and… read more here.
Keywords: anti ctla; ctla antibodies; ctla; cancer ... See more keywords
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Sign Up to like & getrecommendations! Published in 2022 at "NPJ Vaccines"
DOI: 10.1038/s41541-022-00433-9
Abstract: Immune checkpoint inhibitors (ICI) based on anti-CTLA-4 (αCTLA-4) and anti-PD1 (αPD1) are being tested in combination with different therapeutic approaches including other immunotherapies such as neoantigen cancer vaccines (NCV). Here we explored, in two cancer… read more here.
Keywords: cancer; different therapeutic; anti ctla; efficacy ... See more keywords
An anti-CTLA-4 heavy chain–only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2200879119
Abstract: Significance This article describes a fully human therapeutic heavy chain–only antibody for anti-tumor treatment. We show that this anti-CTLA-4 antibody, HCAb 4003-2, has advantageous properties and stimulates anti-tumor T cell activation in several ways: 1)… read more here.
Keywords: anti ctla; heavy chain; chain antibody; tumor ... See more keywords
Anti-CTLA-4 therapy-associated granuloma annulare in chronic myelomonocytic leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Baylor University Medical Center Proceedings"
DOI: 10.1080/08998280.2020.1818165
Abstract: Abstract Immune checkpoint inhibitor (ICI) therapies activate the immune system to unmask cancer cells that the body might otherwise not detect. These cancer therapies alter the immune system at different “checkpoint” proteins such as PD-1,… read more here.
Keywords: anti ctla; ctla therapy; chronic myelomonocytic; therapy ... See more keywords
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
Sign Up to like & getrecommendations! Published in 2017 at "OncoImmunology"
DOI: 10.1080/2162402x.2016.1261242
Abstract: ABSTRACT Despite the success of immune checkpoint blockade in melanoma, the majority of patients do not respond. We hypothesized that the T and NK cell subset frequencies and expression levels of their receptors may predict… read more here.
Keywords: melanoma; tim cells; anti ctla; treatment ... See more keywords
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Immunotherapy (Hagerstown, Md. : 1997)"
DOI: 10.1097/cji.0000000000000470
Abstract: Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus… read more here.
Keywords: anti ctla; stable disease; ctla anti;
Contrasting effects of cyclophosphamide on anti‐CTL‐associated protein 4 blockade therapy in two mouse tumor models
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Science"
DOI: 10.1111/cas.13337
Abstract: Immune checkpoint blockade is a promising anticancer therapy, but must be used in combination with other anticancer therapies to increase its therapeutic efficacy. Cyclophosphamide (CP) is a chemotherapeutic drug that shows immune‐modulating effects. In this… read more here.
Keywords: anti ctla; therapy two; effect; therapy ... See more keywords